Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMatthew WhitesellEADA Business SchoolZSZhaohui SuAIR Worldwide (United States)IZIra ZackonEADA Business School

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals increasing use of bispecific antibodies in multiple myeloma, indicating improved outcomes and evolving treatment strategies.

Key Points

  • To assess the uptake and patient characteristics of bispecific antibodies in relapsed/refractory multiple myeloma in a community oncology network.
  • Retrospective observational cohort study using data from an oncology-specific electronic health record system.
  • Included adult patients with active relapsed/refractory multiple myeloma initiating qualifying therapy between 2022-2025.
  • Patients were categorized into two cohorts: those receiving bispecific antibodies and those not receiving them.
  • 751 patients included: 405 in bispecific antibody cohort and 346 in non-bispecific cohort.
  • Higher median overall survival for bispecific antibody cohort at 22.0 months compared to 16.0 months for non-bispecific cohort.
  • Uptake of bispecific antibodies increased from 4.7% in 2022 to 72.9% by July 2025 in the community oncology setting.

Cite This Study

Whitesell et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d686https://doi.org/10.1182/blood-2025-5857
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  2. 2Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.2024 · 8 citations
  3. 3Age-stratified late outcomes following bispecific antibody therapy in multiple myeloma: A real-world 6-month landmark analysis.2026
  4. 4The bispecific blind spot: Uncovering real-world inequities in diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma therapy access2025
  5. 5A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma2025 · 10 citations